Zeiss Meditec, a prominent medical technology firm based in eastern Germany, has seen its Chinese market continue to be a significant revenue contributor, accounting for approximately a quarter of their total earnings. The company's financial year was marked by a fluctuating landscape as the coronavirus pandemic impacted demand and prompted governmental policy adjustments, including new intraocular lens procurement systems.
Despite a slight decline in earnings due to unfavorable product mix and investments, medical technology sales worldwide – including in China – remain robust, driven by the increasing prevalence of widespread eye diseases such as short-sightedness and cataracts. Though the Chinese market has shown somewhat slower growth, Zeiss Meditec expects to match the overall market expansion for the next financial year.
China is identified as an essential market for the company, with the group's CEO emphasizing its appeal and market strength there. The medium-term outlook for Zeiss Meditec remains optimistic, given the long-term prediction for demand continuity and growth.
However, temporary hurdles prevail. The emergence of new government procurement systems in the intraocular lens market in China has led to a modest slowdown in the company's growth pace. Despite the positive overall performance of the Asia region in 2022-23, the Chinese and Korean markets exhibited slight declines for Zeiss Meditec.
The enterprise employs over 4800 individuals across Germany and abroad, with a specialization in devices and materials for eye disease treatment.
Source:
COVID-19's impact on Zeiss Meditec's Chinese operations was substantial, leading to a double-edged outcome. While initial demand surged due to pandemic-related health concerns, the subsequent market normalization after China's reopening and systemic adjustments have presented challenges.
The Chinese government imposed Volume-Based Procurement (VBP) systems for Intraocular Lenses (IOLs), which led to lowered prices, affecting Zeiss Meditec's revenue margins. Although the increase in volume partially offset the revenue decrease, the overall consequence was a decline in earnings.
Market shifts also played a role in Zeiss Meditec's financial performance. The preference for less expensive LASIK procedures rather than higher-margin SMILE therapies has lessened the contribution of the latter. To counteract these changes, the company is debuting the VisuMax 800 platform, aiming to boost higher-value consumables and enhance revenue margins.
Long-term projections for the Chinese market remain encouraging due to affordability improvements and the growing IOL demand driven by the high prevalence of cataracts and an aging population, despite temporary difficulties.
In summary, Zeiss Meditec's Chinese market has undergone complex shifts in light of the COVID-19 pandemic and governmental policy modifications. Though temporarily affected, the company maintains optimism about the medium and long-term prospects in the Chinese market and is taking strategic measures to adapt to market fluctuations.
